Barone C, Grillo R, Dongiovanni D, Birocco N, Rampino M, Redda M G Ruo, Garibaldi E, Munoz F, Pecorari G, Cavalot A, Garzinodemo P, Buffoni L, Ciuffreda L, Ricardi U, Cortesina G, Giordano C, Fasolis M, Berrone S, Bertetto O, Schena M
UOA Oncologia Medica, COES, Azienda Ospedaliera San Giovanni Battista, Torino, Italy.
Anticancer Res. 2008 Mar-Apr;28(2B):1285-91.
A phase II study was carried out to investigate an induction regimen with cisplatin, paclitaxel followed by radiotherapy concurrent with weekly cisplatin for locally advanced squamous cell carcinoma of the head and neck.
Stage III-IV disease patients were eligible. Two cisplatin (100 mg/m2) and paclitaxel (175 mg/m2) courses were administered every 21 days followed by standard fractionated external beam radiotherapy (approximately 70 Gy), concomitant to weekly cisplatin (30 mg/m2).
Thirty-five patients were enrolled: over 70% had unresectable disease with bulky lesions. Grade 3-4 neutropenia developed in 14% and G3 mucositis in 23%. Locoregional control was achieved in 51%. Median time to progression and overall survival were 10,7 and 17 months respectively; 2- and 3-year survival rates were 30% and 25% respectively.
Our induction two-drug regimen followed by chemoradiotherapy with concurrent weekly cisplatin was well tolerated with low acute toxicity and good locoregional control and survival rate.
开展了一项II期研究，以调查顺铂、紫杉醇诱导方案，随后进行放疗并同期每周给予顺铂，用于治疗局部晚期头颈部鳞状细胞癌。
III-IV期疾病患者符合条件。每21天给予两个疗程的顺铂（100 mg/m²）和紫杉醇（175 mg/m²），随后进行标准分割外照射放疗（约70 Gy），同期每周给予顺铂（30 mg/m²）。
入组35例患者：超过70%患有不可切除疾病且有巨大肿块。14%出现3-4级中性粒细胞减少，23%出现3级黏膜炎。局部区域控制率为51%。中位进展时间和总生存期分别为10.7个月和17个月；2年和3年生存率分别为30%和25%。
我们的两药诱导方案，随后进行同期每周顺铂的放化疗，耐受性良好，急性毒性低，局部区域控制良好，生存率高。
